European journal of clinical pharmacology
-
Eur. J. Clin. Pharmacol. · Jul 2016
Clinical TrialPopulation pharmacokinetics and probability of target attainment of meropenem in critically ill patients.
Patients admitted to intensive care unit (ICU) with Klebsiella pneumoniae infections are characterized by high mortality. The aims of the present study were to investigate the population pharmacokinetics parameters and to assess the probability of target attainment of meropenem in critically ill patients to provide information for more effective regimens. ⋯ Several factors may influence meropenem pharmacokinetics in ICU patients. Continuous i.v. infusions of meropenem seem to be more effective than standard regimens to achieve optimal therapeutic targets.
-
Eur. J. Clin. Pharmacol. · Jul 2016
Clinical TrialPharmacokinetics of cefoperazone/sulbactam in critically ill patients receiving continuous venovenous hemofiltration.
Cefoperazone/sulbactam (CFP/SUL) is a β-lactam/β-lactamase inhibitor combination with little data available for the development of effective dosing guidelines during continuous renal replacement therapy. This study aimed to investigate the pharmacokinetics (PK) of cefoperazone/sulbactam in critically ill patients on continuous venovenous hemofiltration (CVVH). ⋯ PK of cefoperazone/sulbactam was altered in critically ill patients undergoing CVVH. Therapeutic drug monitoring would be recommended to individualize the dose regimen.